SEMA6D

Across TCGA pan-cancer cohorts, SEMA6D mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated SEMA6D data layer compared with 26 for mass-spec protein and 8 for mutation status.

The strongest signal is observed in glioblastoma multiforme (GBM), where higher SEMA6D mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated SEMA6D expression acts as an unfavorable survival marker, although some lineages such as GBM show a favorable association.

GBM, LSCC, and CCRCC are the cancer types where SEMA6D mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
GBM	OS	Median	All	0.506	0.275	.010	9	view →
LSCC	DFS	Median	II,III,IV	0.198	0.887	.024	8	view →
CCRCC	OS	Median	II,III,IV	0.149	1.000	.038	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

SEMA6D–GBM (OS)

Open the GBM breakdown →